| abstract |
The invention relates to the treatment of cancer. More specifically, the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and squamous cell carcinoma. lung, peritoneum cancer, hepatocellular cancer, stomach or gastric cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepaotma, breast cancer, colon cancer, colorectal cancer , endometrial or uterine carcinoma, salivary gland carcinoma, kidney or kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver carcinoma and various types of head and neck cancer, as well as lymphoma B cell including follicular / low grade non-Hodgkin lymphoma (NHL); Small lymphocytic NHL (SL); Follicular NHL / intermediate grade; Diffuse intermediate grade NHL; High grade immunoblastic NHL; High grade lymphoblastic NHL; Small grade small non-cleaved NHLs; NHL with large tumor burden disease; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hair cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phacomatosis, edema such as that associated with brain tumors, Meigs syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and squamous cell carcinoma, by the administration of antibodies directed to a2β1 integrin. |